ATE392214T1 - Impfstoff gegen geschlechtlich übertragene krankheiten - Google Patents

Impfstoff gegen geschlechtlich übertragene krankheiten

Info

Publication number
ATE392214T1
ATE392214T1 AT99969034T AT99969034T ATE392214T1 AT E392214 T1 ATE392214 T1 AT E392214T1 AT 99969034 T AT99969034 T AT 99969034T AT 99969034 T AT99969034 T AT 99969034T AT E392214 T1 ATE392214 T1 AT E392214T1
Authority
AT
Austria
Prior art keywords
vaccine against
sexually transmitted
transmitted diseases
against sexually
diseases
Prior art date
Application number
AT99969034T
Other languages
English (en)
Inventor
Moncef Slaoui
Pierre G Vandepapeliere
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE392214(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE392214T1 publication Critical patent/ATE392214T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99969034T 1998-09-11 1999-09-08 Impfstoff gegen geschlechtlich übertragene krankheiten ATE392214T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use

Publications (1)

Publication Number Publication Date
ATE392214T1 true ATE392214T1 (de) 2008-05-15

Family

ID=10838766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969034T ATE392214T1 (de) 1998-09-11 1999-09-08 Impfstoff gegen geschlechtlich übertragene krankheiten

Country Status (28)

Country Link
EP (1) EP1109574B1 (de)
JP (1) JP2002524532A (de)
KR (1) KR100777896B1 (de)
CN (2) CN101130070A (de)
AR (1) AR021798A1 (de)
AT (1) ATE392214T1 (de)
AU (1) AU744989B2 (de)
BR (1) BR9913630A (de)
CA (1) CA2343399C (de)
CO (1) CO5090882A1 (de)
CY (1) CY1108147T1 (de)
CZ (1) CZ302808B6 (de)
DE (1) DE69938555T2 (de)
DK (1) DK1109574T3 (de)
ES (1) ES2304068T3 (de)
GB (1) GB9819898D0 (de)
HU (1) HUP0104297A3 (de)
IL (1) IL141843A0 (de)
MY (1) MY122216A (de)
NO (1) NO329522B1 (de)
NZ (1) NZ510425A (de)
PL (1) PL199545B1 (de)
PT (1) PT1109574E (de)
SI (1) SI1109574T1 (de)
TR (1) TR200100948T2 (de)
TW (1) TWI225790B (de)
WO (1) WO2000015255A1 (de)
ZA (1) ZA200101987B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP1998800A2 (de) 2006-01-18 2008-12-10 University Of Chicago Zusammensetzungen und verfahren in verbindung mit stayphylokokken-bakterienproteinen
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2443250B8 (de) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA Komplement-vermittelte antikörper-abhängige und opsonische bakterienassays mit hohem durchlauf
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
ES2643498T3 (es) 2010-04-08 2017-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ensayo de células presentadoras de antígenos de linfocitos B
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
EP2726097A4 (de) 2011-07-01 2015-03-11 Univ California Herpes-virus-impfstoff und verwendungsverfahren
US10052329B2 (en) * 2014-07-07 2018-08-21 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
KR20180115276A (ko) 2016-02-22 2018-10-22 베링거잉겔하임베트메디카게엠베하 생체 분자의 고정화 방법
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
NZ510425A (en) 2003-04-29
EP1109574A1 (de) 2001-06-27
AU5975299A (en) 2000-04-03
CN101130070A (zh) 2008-02-27
CN1325311A (zh) 2001-12-05
MY122216A (en) 2006-03-31
PL346651A1 (en) 2002-02-25
NO20011193D0 (no) 2001-03-08
HUP0104297A2 (hu) 2002-03-28
TWI225790B (en) 2005-01-01
CA2343399C (en) 2010-08-03
HUP0104297A3 (en) 2004-10-28
WO2000015255A1 (en) 2000-03-23
NO329522B1 (no) 2010-11-01
GB9819898D0 (en) 1998-11-04
DE69938555D1 (de) 2008-05-29
NO20011193L (no) 2001-05-09
KR20010075049A (ko) 2001-08-09
SI1109574T1 (sl) 2008-08-31
CA2343399A1 (en) 2000-03-23
CZ302808B6 (cs) 2011-11-23
AR021798A1 (es) 2002-08-07
KR100777896B1 (ko) 2007-11-27
CY1108147T1 (el) 2014-02-12
HK1037978A1 (en) 2002-03-01
ES2304068T3 (es) 2008-09-01
JP2002524532A (ja) 2002-08-06
CZ2001887A3 (cs) 2001-10-17
BR9913630A (pt) 2001-05-22
ZA200101987B (en) 2002-05-09
CO5090882A1 (es) 2001-10-30
PL199545B1 (pl) 2008-09-30
DK1109574T3 (da) 2008-06-30
PT1109574E (pt) 2008-06-12
DE69938555T2 (de) 2009-06-10
EP1109574B1 (de) 2008-04-16
TR200100948T2 (tr) 2001-07-23
IL141843A0 (en) 2002-03-10
AU744989B2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
NO20014323D0 (no) Vaksine
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
NO20006191D0 (no) Vaksine
NO20031483L (no) Vaksine
DK1637127T3 (da) Terapeutisk mikroskum
ID27841A (id) Turunan-turunan biaril terapeutik
NO20024172L (no) Vaksine
DE60019672D1 (de) Flacher Fussschalter
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763L (no) Vaksine
DE60008906D1 (de) Medizinische zange
DE50111261D1 (de) Röntgensystem
DK1109574T3 (da) Vaccine mod seksuelt overförte sygdomme
ATE348582T1 (de) Kondom
NO20005599D0 (no) Vaksine
EP1105154A4 (de) Impfstoffe gegen bakterielle superantigene
ATE295687T1 (de) Gegen pflanzenkrankheiten verwendbare pseudomycine
ATE431415T1 (de) Hiv impfstoff
SE0102635D0 (sv) Kondom
SE0100245D0 (sv) Kondom
ITCA20000013A0 (it) Cuscino ortopedico universale
SK2649U (sk) Prezervatív so stimulačným účinkom
FI4458U1 (fi) Savusauna
BR9700175A (pt) Preservativo para sexo oral
SE0102824D0 (sv) Preventivmedel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1109574

Country of ref document: EP